Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever

---

Atıf İçin Kopyala

Ugurlu S., Hacioglu A., Adibnia Y., Hamuryudan V., Ozdogan H.

ORPHANET JOURNAL OF RARE DISEASES, cilt.12, 2017 (SCI-Expanded)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 12
• Basım Tarihi: 2017
• Doi Numarası: 10.1186/s13023-017-0642-0
• Dergi Adı: ORPHANET JOURNAL OF RARE DISEASES
• Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• İstanbul Üniversitesi Adresli: Evet

Özet

Background: There is no established treatment of AA amyloidosis, a long-term complication of various chronic inflammatory diseases associated with increased mortality, such as familial Mediterranian fever (FMF). Recently there are few reports pointing out that tocilizumab(TCZ), an anti IL-6 agent may be effective in AA amyloidosis resistant to conventional treatments. We report our data on the effect of TCZ in patients with FMF complicated with AA amyloidosis.